Under a five-year agreement with the drug and medical device industry, the FDA will receives approximately $6.4 billion in user fees to fund reviews of drugs and medical devices.
Those fees, however, cannot be used until the FDA receives federal funding, which is at stake as $1.2 trillion of federal budget cuts set in through 2012. Under the Budget Control Act, the FDA could lose as much as $200 million for fiscal year 2013. The funding could affect not only product reviews but also jobs at the federal agency.
Lawmakers are currently at a stalemate on whether to comply with the funding cuts required under the Budget Control Act.
More Articles on the FDA:
InVivo Therapeutics Names Interim Chief Science Officer
EOS, IMDS Partner for Medical Devices
NeuroTherm Appoints Gregory Cash as New President & CEO
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.